Table 2.

Univariable Cox regression. Significant results are printed in bold.

Variable	HR (95% CI)	p-Value
Age [years]	1.01 (0.97–1.04)	0.755
ECOG performance status		0.005
- 1 vs. 0	1.30 (0.7–2.7)	0.44
- 2 vs. 0	4.27 (1.3–13.8)	0.015
- 2 vs. < 2	3.76 (1.2–11.6)	0.021
Baseline laboratory parameters
- Total bilirubin [mg/dL]	0.632 (0.19–2.09)	0.45
- AST [U/l]	1.003 (1.00–1.01)	0.33
- ALT [U/l] - AST/ALT ratio - GGT [U/L] - AP [U/L] - Albumin [g/L] - INR - Ammonia [µmol/L] - CA19-9 [U/ml]	0.999 (0.98–1.02) 1.586 (1.08–2.33) 1.002 (1.00–1.00) 1.002 (1.00–1.00) 0.927 (0.86–1.00) 1.487 (0.21–10.77) 1.005 (0.98–1.04 1.000 (1.00–1.00)	0.88 0.018 0.016 0.77 0.045 0.695 0.763 0.021
Hepatopulmonary shunt [%]	1.08 (0.99–1.19)	0.09
Dose reduction
- 20 vs. 0%	1.28 (0.6–2.6)	0.53
- 40 vs. 0%	4.12 (1.2–13.9)	0.022
- 40 vs. 0–20%	3.74 (1.2–12.1)	0.027
- Total tumor burden [%]	1.01 (0.99–1.03)	0.37
- Tumor burden treated lobe [%]	1.01 (0.99–1.03)	0.28
Presence vs. absence of - Bilobar manifestation	1.12 (0.55–2.08)	0.84
- Extrahepatic tumor manifestation	1.45 (0.74–2.84)	0.29
- Thrombosis of the portal vein	1.08 (0.45–2.39)	0.85
- Ascites - Sequential RE - Chemotherapy - Liver surgery - Local liver therapy - Intraarterial therapy	1.99 (0.80–4.94 0.61 (0.19–1.99) 0.92 (0.49–2.22 0.72 (0.37–1.39) 0.86 (0.37–1.97) 0.39 (0.09–1.68)	0.14 0.41 0.92 0.33 0.71 0.21

HR, hazard ratio; 95% CI, 95% confidence interval.